Clinical data | |
---|---|
Other names | BMY 45594 BMS 182751 (OC-6-43)-bis(acetato)amminedichlorocyclohexylamine platinum(IV) |
Routes of administration | Oral |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
UNII | |
ChEBI | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H22Cl2N2O4Pt |
Molar mass | 500.28 g·mol−1 |
3D model (JSmol) | |
| |
(what is this?) (verify) |
Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that was under investigation as a treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration.[1] First mentioned in the medical literature in 1993,[2] satraplatin is the first orally active platinum-based chemotherapeutic drug;[3] other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.
The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.[4]